Ningbo Meishu Pharmaceutical Technology

Ningbo Meishu Pharmaceutical is a Chinese pharmaceutical company specializing in drug development, technology transfer, and commercialization under the Marketing Authorization Holder (MAH) framework. Founded in 2021, the company focuses on therapeutic areas such as metabolic diseases, pain management, dermatology, and cardiovascular health. It operates primarily through a virtual pharma model, outsourcing its research and development to contract research organizations (CROs) and manufacturing to contract manufacturing organizations (CMOs). Its commercial portfolio includes approved generic and improved formulations such as sitagliptin phosphate tablets, loxoprofen sodium gel patches, and minoxidil liniment. Through strategic partnerships with major domestic pharmaceutical entities like Menovo, the company continues to expand its pipeline and market presence in China.